 |
|
| |
Gamma Knife: Revolutionizing Neurosurgery
The Gamma Knife is the worldwide radiosurgical
leader in the non-invasive treatment of malignant
and benign brain tumors, vascular malformations,
and trigeminal neuralgia. |
|
|
The Gamma Knife's impressive accuracy and safety record spans four decades. More than 300,000 patients in over 200 select facilities worldwide have been treated with this technology, and patient outcomes have been documented in over 1,600 clinical publications.
This device has an impressive record of success in treating malignant metastatic brain tumors, trigeminal neuralgia, vascular malformations, and benign tumors such as acoustic neuromas, meningiomas, and pituitary adenomas. It has also been used successfully to treat lung, breast, kidney, and colon tumors, as well as melanomas that have metastasized to the brain. Although often the primary treatment, it can also be used to enhance the results of traditional brain surgery, radiation therapy, and chemotherapy.
Over time after treatment, tumor growth usually stops or reduces and blood vessel abnormalities occlude and dissolve. Many patients experience increased life expectancy and improved quality of life.
Following are treatment results for specific conditions:
| • |
Metastatic tumors: Gamma Knife radiosurgery achieves control rates of 80-85 percent, essentially comparable to open surgery - without the risk of infection, bleeding or complications - and without a lengthy hospital stay and convalescence. |
| |
|
| • |
Trigeminal neuralgia: Trigeminal Neuralgia symptoms typically manifest as a sharp, episodic, shooting pain on one side of the face. It has been reported that in 84% of cases treated by Gamma Knife, patients have experienced pain relief for more than two years without reoccurrence. |
| |
|
| • |
Acoustic neuromas (vestibular schwannomas): Up to 98 percent of tumors either decrease in size or remain stable, with near complete facial nerve preservation, at six-year follow-up. |
| |
|
| • |
Pituitary adenomas: Effective control in a majority of patients; particularly beneficial for residual or recurrent tumors following surgery. |
| |
|
| • |
Vascular malformations such as arteriovenous malformations (AVMs): Complete obliteration of AVMs takes place in 60 to 70 percent of patients within two to three years of treatment. |
| |
|
Click here for more information on the Gamma Knife's impressive track record.
BACK TO TOP |
|
